Bank of Montreal Can Trims Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Bank of Montreal Can lessened its holdings in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 66.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,343 shares of the health services provider's stock after selling 8,750 shares during the quarter. Bank of Montreal Can's holdings in Amedisys were worth $394,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of AMED. Trexquant Investment LP lifted its holdings in Amedisys by 1,317.8% in the 4th quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider's stock worth $7,964,000 after buying an additional 81,532 shares in the last quarter. ABC Arbitrage SA acquired a new stake in Amedisys in the fourth quarter worth $2,522,000. Oddo BHF Asset Management Sas acquired a new stake in shares of Amedisys in the third quarter valued at approximately $7,238,000. Empowered Funds LLC bought a new position in shares of Amedisys in the fourth quarter worth $318,000. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Amedisys in the fourth quarter valued at approximately $590,000. 94.36% of the stock is owned by institutional investors and hedge funds.

Amedisys Price Performance

Shares of AMED stock opened at $92.43 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The stock has a market capitalization of $3.03 billion, a PE ratio of 36.68, a PEG ratio of 1.78 and a beta of 0.89. The stock's fifty day moving average is $92.12 and its 200-day moving average is $91.83. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The business had revenue of $598.05 million for the quarter, compared to the consensus estimate of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Equities research analysts expect that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on AMED shares. Stephens restated an "equal weight" rating and issued a $101.00 price target on shares of Amedisys in a research report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 target price on shares of Amedisys in a research report on Wednesday, April 16th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.